FeesSafety
Pluang+

Edgewise Therapeutics rated speculative buy with $59 target, citing promising drug EDG-7500 and strong cash runway.

Analyst Insights
22 Nov 2026, 03:56 WIB
Seeking Alpha
View Source
Bullish
Edgewise Therapeutics rated speculative buy with $59 target, citing promising drug EDG-7500 and strong cash runway.

Willow Tree Research initiates coverage of Edgewise Therapeutics with a speculative buy rating and a $59 price target, suggesting about 40% upside from current levels. The key driver is the drug EDG-7500, which may offer improved tolerability without the need for routine safety echocardiograms, currently being tested in the STRATUS-HCM trial. The company is valued at around $4.6 billion with a strong cash position of approximately $1.74 billion, supporting operations into 2032. Risks include potential side effects like atrial fibrillation, competition, and manufacturing dependencies.

Edgewise Therapeutics shares are trading at USD 39.91 on Pluang, down 3.07% in the past day. The stock's market cap stands at $4.37 billion as of Nov 22, 2026 09:11 WIB.

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App